Related Experiment Video
Updated: Mar 11, 2026

Acute Kidney Injury Model Induced by Cisplatin in Adult Zebrafish
Published on: May 15, 2021
Beneficial Effects of Myo-Inositol Oxygenase Deficiency in Cisplatin-Induced AKI
Rajesh K Dutta1, Vinay K Kondeti1, Isha Sharma1
1Departments of Pathology and.
Abstract:
Overexpression of the proximal tubular enzyme myo-inositol oxygenase (MIOX) induces oxidant stress in vitro However, the relevance of MIOX to tubular pathobiology remains enigmatic. To investigate the role of MIOX in cisplatin-induced tubular AKI, we generated conditional MIOX-overexpressing transgenic (MIOX-TG) mice and MIOX-knockout (MIOX-/-) mice with tubule-specific MIOX overexpression or knockout, respectively. Compared with cisplatin-treated wild-type (WT) mice, cisplatin-treated MIOX-TG mice had even greater increases in urea, creatinine, and KIM-1 levels and more tubular injury and apoptosis, but these effects were attenuated in cisplatin-treated MIOX-/- mice. Similarly, MIOX-TG mice had the highest and MIOX-/- mice had the lowest renal levels of Bax, cleaved caspase-3, and NADPH oxidase-4 expression and reactive oxygen species (ROS) generation after cisplatin treatment. In vitro, cisplatin dose-dependently increased ROS generation in LLC-PK1 cells. Furthermore, MIOX overexpression in these cells accentuated cisplatin-induced ROS generation and perturbations in the ratio of GSH to oxidized GSH, whereas MIOX-siRNA or N-acetyl cysteine treatment attenuated these effects. Additionally, the cisplatin-induced enhancement of p53 activation, NF-κB binding to DNA, and NF-κB nuclear translocation in WT mice was exacerbated in MIOX-TG mice but absent in MIOX-/- mice. In vitro, MIOX-siRNA or NAC treatment reduced the dose-dependent increase in p53 expression induced by cisplatin. We also observed a remarkable influx of inflammatory cells and upregulation of cytokines in kidneys of cisplatin-treated MIOX-TG mice. Finally, analysis of genomic DNA in WT mice revealed cisplatin-induced hypomethylation of the MIOX promoter. These data suggest that MIOX overexpression exacerbates, whereas MIOX gene disruption protects against, cisplatin-induced AKI.
Insights
Myo-inositol oxygenase (MIOX) overexpression worsens cisplatin-induced acute kidney injury (AKI) by increasing oxidative stress and inflammation. Conversely, MIOX gene disruption protects against AKI, highlighting MIOX as a potential therapeutic target.
Area of Science:
- Nephrology
- Molecular Biology
- Pathobiology
Background:
- Myo-inositol oxygenase (MIOX) overexpression is linked to oxidant stress, but its role in kidney injury is unclear.
- Cisplatin is a nephrotoxic chemotherapy agent causing acute kidney injury (AKI).
- Understanding MIOX's role in AKI pathogenesis is crucial for developing targeted therapies.
Purpose of the Study:
- To investigate the role of MIOX in cisplatin-induced AKI.
- To determine if MIOX overexpression exacerbates or if MIOX knockout mitigates kidney damage.
- To elucidate the molecular mechanisms underlying MIOX's effect on AKI.
Main Methods:
- Generated MIOX-overexpressing (MIOX-TG) and MIOX-knockout (MIOX-/-) mice with tubule-specific MIOX modulation.
- Administered cisplatin to transgenic mice, knockout mice, and wild-type (WT) controls.
- Assessed kidney function (urea, creatinine, KIM-1), tubular injury, apoptosis, oxidative stress markers (ROS, GSH/GSSG), inflammatory markers, and key signaling pathways (p53, NF-κB) in vivo and in vitro.
Main Results:
- MIOX-TG mice showed exacerbated cisplatin-induced AKI, increased renal oxidative stress, apoptosis, and inflammation compared to WT mice.
- MIOX-/- mice exhibited attenuated cisplatin-induced AKI, reduced oxidative stress, and less apoptosis.
- MIOX overexpression amplified cisplatin-induced ROS generation and p53/NF-κB activation, while MIOX knockout diminished these effects.
Conclusions:
- MIOX overexpression exacerbates cisplatin-induced AKI through increased oxidative stress and inflammation.
- MIOX gene disruption provides protection against cisplatin nephrotoxicity.
- MIOX is a key mediator in AKI pathogenesis and a potential therapeutic target for kidney protection.
Related Concept Videos
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Acute Kidney Injury II: Pathophysiology
Acute Kidney Injury I: Introduction

